4.7 Article

Recent advances in the management and implementation of care for familial hypercholesterolaemia

Journal

PHARMACOLOGICAL RESEARCH
Volume 194, Issue -, Pages -

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2023.106857

Keywords

Familial hypercholesterolemia; Risk stratification; Cardiovascular diseases; Low density lipoprotein; Cholesterol -lowering therapy

Ask authors/readers for more resources

Familial hypercholesterolaemia (FH) is a common genetic disorder characterized by elevated LDL-C levels and increased risk of ASCVD. Many patients with FH do not achieve LDL-C goals despite treatment with statins and ezetimibe. New therapies targeting PCSK9 and ANGPTL3 have shown promising results in closing the treatment gap. This review discusses current and emerging treatment strategies for FH and emphasizes the importance of risk-stratification and implementation strategies for patient care.
Familial hypercholesterolaemia (FH) is a common autosomal semi-dominant and highly penetrant disorder of the low-density lipoprotein (LDL) receptor pathway, characterised by lifelong elevated levels of low-density lipo-protein cholesterol (LDL-C) and increased risk of atherosclerotic cardiovascular disease (ASCVD). However, many patients with FH are not diagnosed and do not attain recommended LDL-C goals despite maximally tolerated doses of potent statin and ezetimibe. Over the past decade, several cholesterol-lowering therapies such as those targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) or angiopoietin-like 3 (ANGPTL3) with monoclonal antibody or ribonucleic acid (RNA) approaches have been developed that promise to close the treatment gap. The availability of new therapies with complementary modes of action of lipid metabolism has enabled many patients with FH to attain guideline-recommended LDL-C goals. Emerging therapies for FH include liver-directed gene transfer of the LDLR, vaccines targeting key proteins involved in cholesterol metabolism, and CRISPR-based gene editing of PCSK9 and ANGPTL3, but further clinical trials are required. In this review, current and emerging treatment strategies for lowering LDL-C, and ASCVD risk-stratification, as well as implementation strategies for the care of patients with FH are reviewed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available